Navigation Links
BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences

JERUSALEM--(BUSINESS WIRE)--May 17, 2007 - BioLineRx Ltd. (TASE: BLRX), Israel's leading drug development company, announced today that abstracts containing data from its successfully completed phase I clinical trails of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, have been accepted for poster presentations at three leading scientific conferences. The data will be presented at the following conferences:

-- Society of Biological Psychiatry Annual Convention, May 17-19 (San Diego)

-- American Psychiatric Association Annual Meeting, May 19-24 (San Diego)

-- New Clinical Drug Evaluation Unit Annual (NCDEU) Meeting, June 11-14 (Boca Raton)

The abstract which has been selected for these poster presentations describes the results of a Phase I, randomized, placebo-controlled double blinded, single dose-escalation study to evaluate the safety and determine the pharmacokinetic profile of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia.

"We are very pleased that these important data regarding the Phase I trials of BL-1020 are being presented at these three major psychiatric conferences. The Phase I studies support our product profile of a highly efficacious antipsychotic devoid of extrapyramidal symptoms or metabolic side effects," commented Morris Laster, chief executive officer of BioLineRx. "We continue to believe that the compound holds great promise for the treatment of schizophrenia, which currently poses an intractable medical problem for physicians and patients. We very much look forward to the initiation of the Phase II trial in the second quarter of 2007."

About BL-1020

BL-1020 is an orally available GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. Data from preclinical and phase I studies demonstrated that the compound may retain the efficacy of currently available typical and atypical antipsychotic drugs while achieving a much higher safety profile as evidenced by a lack of metabolic or extrapyramidal side effects.

BL-1020 is being developed by BioLineRx, Ltd. under a worldwide exclusive license from Ramot at Tel Aviv University Ltd. and Bar-Ilan Research and Development Company Ltd., the technology transfer arms of Tel Aviv University and Bar-Ilan University respectively. BL-1020 was discovered by Professor Abraham Nudelman from the Department of Chemistry, Bar-Ilan University; and Ada Rephaeli, Ph.D., Professor Abraham Weizman, MD, and Irit Gil-Ad, Ph.D. from the Sackler Faculty of Medicine, Tel Aviv University.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE: BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are for schizophrenia and treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx seeks to enrich the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd, Giza, Pitango, Hadasit and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.

This press release contains "forward-looking statements." These statements include words like "may," "expects," "believes," "scheduled" and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Contact

BioLineRx Ltd.
VP Finance and Corporate Development
Yuri Shoshan, +972-2-548-9100
yuri@biolinerx.com
Tsipi Haitovsky, +972-52-598-9892
Media Liaison
tsipih@biolinerx.com
or
Stern Investor Relations, Inc.
Melanie Friedman, 212-362-1200
melanie@sternir.com


'"/>




Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017 A new Transparency Market Research ... was valued at US$0.53 bn in 2013 and is predicted to ... CAGR between 2014 and 2022. The title of the report is ... Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred ...
(Date:1/23/2017)... SAN FRANCISCO , January 23, 2017 The global  ... USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated ... and psychotherapies has resulted in the declining demand for antidepressants in the recent ... ... Grand View Research Logo ...
(Date:1/23/2017)... SAN DIEGO , 23. Januar 2017  ResMed ... China ) und 3B Medical ( Winter ... sich auf eine Vereinbarung über die Beilegung aller globalen ... ist der Verkauf ihrer bestehenden Produkte im ... eine einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... , ... METTLER TOLEDO has announced the availability of a ... Tools . , Crystallization is a common step used during the ... now spend more time developing better intermediate and final crystallization steps. By ...
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers ... Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. ... bodybuilder in 2012 and in less than a year was able to turn professional, ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/23/2017)... ... 2017 , ... Valentine’s Day is a time when many people celebrate romance and love by ... be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a ... Or, spend $200 and get $50 free. , “A lot of people just buy ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals ... of a simple test will take days to arrive to the end customer, having ... direct access to their lab tests, bypassing the cost and delay of traditional means. ...
Breaking Medicine News(10 mins):